ExpreS2ion will participate in key investor and industry events in October 2021

ExpreS2ion Biotech Holding AB (“ExpreS2ion") will participate and hold presentations at key investor and industry events in October. These include events hosted by HC Andersen Capital as well as the World Vaccine Congress and BIO-EUROPE.

To participate, please register or find more information via the links below. Additional information and updates can be found on the Meet Us page of the ExpreS²ion website.

HC Andersen Capital – Potential value of COVID-19 vaccine candidate (in Danish), October 14
Virtual
Join CEO Bent Frandsen in taking a dive deeper into the economy and the potential for ExpreS²ion on their COVID-19 vaccine candidate, including milestones and license royalty payments.
Register via HC Andersen Capital's website.

World Vaccine Congress Europe, October 19-21
Barcelona, Spain
To learn more about the ExpreS² system and our development pipeline, see Eske Rygaard-Hjalsted, VP Business Development, at booth 27 in Barcelona. Pre-arrange meetings via email on info@expreS2ionbio.com.
Register via World Vaccine Congress website. 

BIO-EUROPE, October 25-28
Virtual
One of the major partnering events for pharmaceutical and biotechnology companies. Pre-arrange meetings via email on info@expreS2ionbio.com, or use the BIO-EUROPE partnering system.
Register via the BIO-EUROPE website.

Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se

For further information about ExpreS²ion, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS²ion develops novel capsid VLP based vaccines through its 34% owned joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com.